Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of August 2017. The filing incorporates by reference the company's unaudited interim financial results for the period ended June 30, 2017, which were announced via press release on August 31, 2017.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached Exhibit 99.2 (unaudited financial statements), which is referenced but not included in the provided text.
Material Changes and Corporate Actions
- Voluntary Delisting: The Board of Directors decided to voluntarily delist the company's shares from the Tel Aviv Stock Exchange (TASE) by the end of 2017, while maintaining its listing on NASDAQ.
- Leadership Transition: The Board formed a committee to identify a new Chairman of the Board with global experience to guide upcoming Phase 3 trials and commercialization.
- Current Chairmanship: Professor Avner Rotman will continue to serve as Chairman until a replacement is identified.
Outlook, Risks, and Management Commentary
Management indicated that the search for a new Chairman is driven by the need for global experience to support anticipated international Phase 3 trials and global commercialization efforts. The delisting from TASE is a strategic move to consolidate trading on NASDAQ. No specific financial guidance or risk factors were detailed in the text of this Form 6-K, other than the operational changes noted above.
Investor Verification Checklist
- Review Exhibit 99.2 for specific financial performance data (revenue, net loss, cash position) for the period ended June 30, 2017.
- Monitor the timeline and regulatory approval for the TASE delisting process expected to conclude by the end of 2017.
- Track the progress of the committee searching for a new Chairman of the Board.
- Verify the status of the company's international Phase 3 clinical trials mentioned as a strategic priority.